New York, March 3, 2026, 15:29 EST — Regular session
- RKLB edged up 0.3% to $71.16 late, following a volatile session that saw the stock move almost 10% intraday.
- CEO Peter Beck is looking to unload as many as 28,761 shares, according to a Form 144 filing—roughly $2.0 million worth.
- Cantor Fitzgerald bumped its price target to $85, while other firms tweaked their outlooks following the Neutron timeline delay.
Rocket Lab Corporation shares whipsawed on Tuesday following news that founder and CEO Peter Beck had filed to offload some stock. A broker also bumped up its price target on the space company. The shares were recently up 19 cents, or roughly 0.3%, at $71.16 in afternoon trading, after bouncing between $66.19 and $73.25.
Rocket Lab has become a quick-trigger play for traders these days, with defense contracts, gains in its space-systems arm, and a lagging rocket rollout each yanking the stock up or down.
Insider-sale filings tend to sting more when the stock’s already dealing with timing risk. For Rocket Lab, though, it’s execution that matters most now. Headlines won’t be the next catalyst.
A Form 144 filed March 2 identified Beck as the account holder set to sell up to 28,761 common shares, with Morgan Stanley Smith Barney’s executive services handling the proposed transaction. The document pegged the shares’ total market value at roughly $2.0 million and noted they came from restricted stock that vested March 1. No sales had occurred over the previous three months, according to the filing.
Form 144 signals that someone is planning to unload restricted or “control” securities, as set out by SEC Rule 144. This filing doesn’t promise a sale, but it tips off traders to possible selling pressure ahead.
Cantor Fitzgerald’s Andres Sheppard bumped up his price target on Rocket Lab, lifting it to $85 from $72 while maintaining an Overweight call. According to Sheppard, the Geost deal “adds payloads as a new category of offering, and should position Rocket as a disruptive prime contractor for U.S. National Security Missions.” TipRanks
Not everyone agrees. Needham trimmed its price target to $95, citing the Neutron delay, but kept its Buy rating, Investing.com reported.
Rocket Lab posted its highest-ever annual revenue last week, coming in at $602 million. The company wrapped up 2025 holding a contracted backlog of $1.85 billion. “Delivered record quarterly revenue of $180 million,” CEO Peter Beck said, with that total pushing full-year revenue to the new high. The same announcement noted Neutron’s first launch—delayed after a stage 1 tank test failure—is now scheduled for the fourth quarter of 2026. SEC
The Neutron timeline still looms as the key threat to the stock. Any additional delays, or hints that costs are climbing, might chip away at the bullish thesis—even if upcoming launches and space-systems contracts keep activity high.
Traders are waiting to see follow-on filings that confirm if the proposed sales made it to market, plus any new details on Neutron testing milestones. Rocket Lab’s next earnings report is slated for May 7, according to earnings calendars.
